Skip to main content

Table 4 Percentage of 9 Classic Subsets Expressing PD-L1

From: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

PT

PT3

PT7

PT11

PT14

Median of PTs

HD1

HD2

Median of HDs

Days Post Tx

D98

D561

D456

D596

D448

PD-L1 + CD4

1.9

1.2

1.5

1.6

1.5

1.5

0.7

0.5

0.6

PD-L1 + CD8

0.9

0.9

0.6

1.1

1.8

0.9

1.6

0.8

1.2

PD-L1 + Treg

0.3

0.1

0.8

0.6

0.6

0.6

0.2

0.1

0.2

PD-L1 + NK

3.1

1.8

1.3

1.3

1.6

1.6

1.0

0.5

0.8

PD-L1 + NKT

38.2

1.5

0.8

0.8

1.6

1.5

2.2

0.9

1.5

PD-L1 + B cells

19.45

6.75

14.12

12.83

13.14

13.1

29.32

14.00

21.7

PD-L1 + cDc

25.6

2.2

2.5

3.3

5.5

3.3

4.3

1.3

2.8

PD-L1 + pDc

< 0.01

< 0.01

< 0.01

< 0.01

< 0.01

< 0.01

< 0.01

< 0.01

< 0.01

PD-L1 + MDSC

19.34

11.81

10.12

11.42

15.11

11.8

4.37

5.76

5.1

  1. Expression of PD-L1 in 9 classic subsets was measured by flow cytometry in 4 patients, where PBMCs were available, after treatment with durvalumab and olaparib. Results are displayed as % of classic subsets that express PD-L1. cDC conventional dendritic cells, MDSC myeloid derived suppressor cell, NK natural killer, pDC plasmacytoid DC, PD-L1 programmed cell death ligand-1, Tregs regulatory T cells